A case of reversible cerebral vasoconstriction syndrome developing during treatment of adult aplastic anemia

Akira Yamamoto1 · Yusuke Meguri1,2 · Akiko Fukuda1,3 · Yui Kambara1 · Tomohiro Urata1 · Taiga Kuroi1 · Taro Masunari1 · Nobuo Sezaki1 · Toru Kiguchi1

Received: 29 January 2018 / Accepted: 1 July 2018 / Published online: 10 July 2018 © The Author(s) 2018

Dear Editor,

Reversible cerebral vasoconstriction syndrome (RCVS) refers to a group of disorders characterized by “thunderclap headaches” and diffuse narrowing of the cerebral arteries [1]. RCVS sometimes develops after the use of immunosuppressants that are frequently used to treat hematological diseases. However, only two pediatric cases of RCVS in patients with a hematological disease have been reported [2, 3]. Herein, we report the first adult case of RCVS in a patient with aplastic anemia (AA).

A 58-year-old female presented with a severe headache and hypertension on day 5 after commencement of oral cyclosporine A (CsA) and rabbit anti-thymocyte globulin (ATG) to treat severe AA. Initially, she was given analgesics for the headache and CsA because head CT scans showed no evidence of bleeding of the brain. However, her headache persisted, and we stopped CsA on day 11. Thereafter, her headache ceased, but on day 13, she complained of a bilateral visual field defect. Magnetic resonance imaging revealed multiple small cerebral infarctions, and magnetic resonance angiography (MRA) revealed diffuse vasoconstrictions of the cerebral arteries (Fig. 1). Her neurological findings and cerebral images gradually improved. On day 217, she was retreated with low-dose CsA and exhibited no neural sequelae. The blood cell numbers increased, but she remained transfusion-dependent (except for platelets); we scheduled monthly erythrocyte transfusions.

It is important to reduce or stop a drug that is causing RCVS, such as CsA and rabbit-ATG [2, 3]. The hypertension and thunderclap headaches ceased immediately after CsA was stopped, but the possibility that rabbit-ATG induced RCVS cannot be discounted.

Magnesium sulfate [4] and calcium antagonists [3, 5] are useful RCVS therapies, reducing blood pressure and dilating the cerebral vessels. Retreatment of AA with CsA is sometimes inevitable; Ueki et al. retreated AA by CsA with lomerizine without relapsing RCVS [3]. As the hypertension improved after CsA was stopped, we did not use calcium antagonists.

We commenced CsA at a low dose and controlled the blood level because side-effect development depends on the CsA blood concentration [6]. A switch to tacrolimus is one possible strategy when posterior reversible encephalopathy syndrome (PRES) develops [7]. Tacrolimus also causes RCVS [8], but is effective against AA [9]. The class effect of the various calcineurin inhibitors on RCVS remains poorly known; these materials may be useful treatment options.

A diagnosis of RCVS requires MRA, but MRA findings are sometimes not initially apparent; repeat MRA is recommended ≥1 week after onset [10]. Only two cases of RCVS in patients with hematological diseases have been reported despite many such patients taking drugs.
that can induce RCVS. The condition may be misdiagnosed, because MRA is not routine; possible erroneous diagnoses include PRES. The prognosis of RCVS is thought to be good, but severe complications such as cerebral hemorrhage and infarctions can develop. Accurate diagnosis via MRA is essential; more cases are required to study whether to restart CsA or switch to tacrolimus to treat AA with a history of RCVS.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give
References

1. Ducros A (2012) Reversible cerebral vasoconstriction syndrome. The Lancet Neurology 11(10):906–917. https://doi.org/10.1016/s1474-4422(12)70135-7

2. Kazato Y, Fuji K, Oba H, Hino M, Ochiai H, Uchikawa H, Kohno Y (2012) Reversible cerebral vasoconstriction syndrome associated with brain parenchymal hemorrhage. Brain Dev 34(8):696–699. https://doi.org/10.1016/j.braindev.2011.11.001

3. Ueki H, Sanayama Y, Miyajima A, Tsuchimochi T, Igarashi S, Sunami S (2016) Reversible cerebral vasoconstriction syndrome promptly diagnosed with magnetic resonance imaging including magnetic resonance angiography during immunosuppressive therapy in a 16-year-old girl with refractory cytopenia of childhood. Hematol Rep 8(4):6673. https://doi.org/10.4081/hr.2016.6673

4. Singhal AB (2004) Postpartum angiopathy with reversible posterior leukoencephalopathy. Arch Neurol 61(3):411–416. https://doi.org/10.1001/archneur.61.3.411

5. Chen SP, Fuh JL, Lirng JF, Chang FC, Wang SJ (2006) Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology 67(12):2164–2169. https://doi.org/10.1212/01.wnl.0000249115.63436.6d

6. Fukuda M, Yano I, Masuda S, Okuda M, Inui K-i (2005) Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J Pharmacol Exp Ther 312(2):816–825. https://doi.org/10.1124/jpet.104.074930

7. Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, Wang X, Lin T (2016) Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine 95(14):e3173. https://doi.org/10.1097/MD.0000000000003173

8. Kumai Y, Seguchi O, Sato T, Wada K, Shiozawa M, Yokota C, Kuroda K, Nakajima S, Sato T, Yanase M, Matsumoto Y, Fukushima S, Fujita T, Kobayashi J, Fukushima N (2017) Reversible cerebral vasoconstriction syndrome after heart transplantation: a case report. Transplant Proc 49(10):2415–2418. https://doi.org/10.1016/j.transproceed.2017.10.016

9. Chiu V, Weitz IC, Hermel DJ (2017) Tacrolimus is effective immunosuppressive therapy in aplastic anemia. Blood 130(Suppl 1): 1183–1183

10. Ducros A, Fiedler U, Porcher R, Boukobza M, Stupf C, Bousser MG (2010) Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke 41(11):2505–2511. https://doi.org/10.1161/strokeaha.109.572313